Eric Pauwels Net Worth

The estimated Net Worth of Eric Pauwels is at least $4.13 Milion dollars as of 17 April 2024. Mr. Pauwels owns over 787 units of PTC Therapeutics Inc stock worth over $2,184,485 and over the last 14 years he sold PTCT stock worth over $1,941,767. In addition, he makes $0 as Chief Business Officer at PTC Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Pauwels PTCT stock SEC Form 4 insiders trading

Eric has made over 20 trades of the PTC Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 787 units of PTCT stock worth $19,785 on 17 April 2024.

The largest trade he's ever made was selling 8,836 units of PTC Therapeutics Inc stock on 17 May 2023 worth over $517,083. On average, Eric trades about 1,506 units every 50 days since 2011. As of 17 April 2024 he still owns at least 67,694 units of PTC Therapeutics Inc stock.

You can see the complete history of Mr. Pauwels stock trades at the bottom of the page.

Eric Pauwels biography

Eric Pauwels serves as Chief Business Officer of the Company. Mr. Pauwels has 34 years of healthcare experience in biopharmaceuticals and medical devices. Mr. Pauwels joined the Company in March 2015 as Senior Vice President and General Manager of the Americas. He also serves as a director of a subsidiary of PTC. From September 2011 until March 2015, Mr. Pauwels was the Chief Commercial Officer and President of International for NPS Pharmaceuticals, a publicly traded biopharmaceutical company that was acquired by Shire plc. In 2011, Mr. Pauwels was the Chief Marketing Officer of Accuray Inc. From 2005 to 2010 Mr. Pauwels served as the first Chief Commercial Officer for the Shire Rare Disease Business. Mr. Pauwels earned his B.S. from California State Polytechnic University in Pomona, California.

How old is Eric Pauwels?

Eric Pauwels is 59, he's been the Chief Business Officer of PTC Therapeutics Inc since 2020. There are 10 older and 6 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.

What's Eric Pauwels's mailing address?

Eric's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059.

Insiders trading at PTC Therapeutics Inc

Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel a Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.

What does PTC Therapeutics Inc do?

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.

Complete history of Mr. Pauwels stock trades at Accuray Inc a PTC Therapeutics Inc

PTC Therapeutics Inc executives and stock owners

PTC Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stuart Peltz,
  Chief Executive Officer, Director
• Neil Almstead,
  Chief Technical Operations Officer
• Mark Boulding,
  Executive Vice President, Chief Legal Officer
• Emily Hill,
  Principal Financial Officer, Treasurer
• Dr. Stuart W. Peltz,
  Co-Founder, CEO & Exec. Director
• Christine Utter,
  Senior Vice President - Finance, Chief Accounting Officer
• Mark Elliott Boulding,
  Exec. VP & Chief Legal Officer
• Dr. Neil Almstead,
  Chief Technical Operations Officer
• Michael Schmertzler,
  Independent Chairman of the Board
• Allan Jacobson,
  Independent Director
• Emma Reeve,
  Independent Director
• David Southwell,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Glenn Steele,
  Independent Director
• Jerome Zeldis,
  Independent Director
• Stephanie Okey,
  Independent Director
• Dr. Allan Steven Jacobson,
  Independent Co-Founder, Chairman of Scientific Advisory Board & Director
• Eric Pauwels,
  Chief Business Officer
• Matthew Klein,
  Chief Development Officer
• Jane Baj,
  VP of Corp. Communications
• Alex Kane,
  Investor Relations Officer
• Ellen Welch Ph.D.,
  Chief Scientific Officer
• Christine Utter,
  Sr. VP, Chief Accounting Officer & Head of People Services
• Adam Koppel,
  Director
• Cameron Geoffrey Mc Donough,
  Director
• Tuyen Ong,
  Chief Medical Officer
• Marcio Souza,
  Chief Operating Officer
• Pharma Holdings Ii, Llc Com...,
  10% owner
• Mark Rothera,
  Chief Commercial Officer
• Ronald C Jr Renaud,
  Director
• Suisse/ Credit,
  
• Claudia De Oliveira Ribeiro...,
  President
• Bioventures Cayman Ltd Hbm,
  10% owner
• Robert J. Spiegel,
  Chief Medical Officer
• Richard Aldrich,
  Director
• Ventures Inc.Vulcan Capital...,
  
• Shane William Charles Kovacs,
  EVP, CFO & Head of Corp Dev
• Axel Bolte,
  Director
• Michael L Kranda,
  Director
• Pierre Gravier,
  CHIEF FINANCIAL OFFICER
• Mary L. Smith,
  
• William F. Jr. Bell,
  
• Alethia Young,
  
• Lee Scott Golden,
  EVP & CHIEF MEDICAL OFFICER